SABS · SAB Biotherapeutics, Inc.

0001193125-26-218195

Summary

Q1 2026 losses widened significantly with operating income at -$20.0M (-85.6% YoY) and net income at -$18.9M (-263.1% YoY), driven by intensified investment in SAB-142 development and higher cash utilization, partially offset by EPS improvement to -$0.35 (37.5% YoY).

Key takeaways

Operating income declined 85.6% YoY to -$20.0M as the Company continued investing in development of lead product candidate SAB-142.
Net income deteriorated 263.1% YoY to -$18.9M amid working capital fluctuations supporting clinical advancement.
Diluted EPS improved 37.5% YoY to -$0.35, reflecting changes in share structure following recent equity activities.
Operating cash use increased to -$14.3M, reflecting year-over-year rise in cash needs for SAB-142 program execution.

Full analysis

Looking forward, losses are expected to persist and grow as SAB-142 advances through development, regulatory pursuits, and potential commercialization. Investors should track platform execution, cash preservation via short-term investments, and fundraising to extend runway amid escalating burn. The filing signals disciplined capital allocation but underscores biopharma's inherent loss trajectory pre-revenue.